INTRODUCTION
In July 2012, Congress passed the Advancing Breakthrough Therapies for Patients Act as part of the Food and Drug Administration Safety and Innovation Act (FDASIA). Section 902 of FDASIA provides for designation of a drug as a breakthrough therapy Bif the drug is intended alone or in combination with one or more other drugs, to treat serious or life-threatening diseases or conditions and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies (1) .B reakthrough designation is a mechanism that the U.S. Food and Drug Administration (FDA) can grant to sponsors to expedite the development of these promising therapies.
As part of the program, the FDA and sponsor collaborate in a dynamic, multi-disciplinary, resource-intensive process to determine the most efficient path using an Ball hands on deck approachî nvolving senior managers and experienced review staff and more frequent and interactive communications (2, 3) . The objective is to expedite design and review of the clinical development program so that trials are as efficient as possible, and the number of patients exposed to potentially less efficacious treatment is minimized. As a consequence, clinical development timelines involving the traditional three distinct phases could be reduced from 7-10 to 3-5 years.
The shorter clinical development programs will have significant impact on product and process development timelines requiring the manufacturing organization to reconsider traditional approaches to product and process development and undertake their own resource-intensive, cross-functional team approach to ensure a sustained supply of safe and efficacious product at the time of approval. To ensure success, the manufacturing organization should have good communications with the clinical organization to facilitate identification of potential candidates for breakthrough designation early and help gate or accelerate the appropriate Chemistry, Manufacturing, and Controls (CMC) and current Good Manufacturing Practice (cGMP) development activities. It is important to understand that breakthrough drug development programs are resource intensive; sponsors need to be selective about which programs to take forward and ensure management support. Moreover, a collaborative, cross-functional approach between development, commercial, and regulatory operations, with early and robust discussions, is essential to ensure successful development and launch of a breakthrough drug product.
In March of 2015, Friends of Cancer Research (Friends) convened a group of industry and FDA stakeholders familiar with developing breakthrough drugs to explore options, manufacturers of small molecule and biologic products have for front-loading certain critical manufacturing activities to speed development of breakthrough therapy drugs. This expert group also explored options for science-and risk-based approaches to mitigating the potential risk of having less CMC information at the time of launch versus the benefit of having these innovative new products available to patients sooner. The considerations captured in this white paper outline approaches that sponsors have taken to successfully manufacture breakthrough products as well as new approaches that aim to further explore potential efficiencies in bringing breakthrough products to market. These ideas were presented at a public forum, convened by Friends, on June 10 in Washington, DC, in an effort to seek broad feedback on the recommendations put forth to expedite rate-limiting steps in CMC and cGMP for products demonstrating high clinical benefits while ensuring an adequate supply of safe and efficacious product at the time of approval (4) .
BREAKTHROUGH DEVELOPMENT PROGRAMS MAY PUT CMC/GMP ACTIVITIES ON CRITICAL PATH
Timelines for completing CMC/GMP activities for a breakthrough product will be driven by the design of the clinical development program for the breakthrough product. Each development program will vary depending on the complexity of the product, how soon accelerated CMC development activities begin, availability of platform technology, relevant prior knowledge, and timing of designation. If the breakthrough designation is granted at an early development stage following promising preliminary clinical data, some of the phase III CMC-enabling activities may need to be accelerated. On the other hand, if a breakthrough designation is granted to a product in late stage development, the challenges for manufacturing readiness may be less burdensome but may also need to be addressed in a more compressed time frame. While drugs approved under the breakthrough pathway still need to meet statutory requirement for product quality, safety, and efficacy, balancing risk to product quality and availability for patients is critical. Therefore, development of breakthrough drugs necessitates risk-based approaches to product and process development, commercial readiness, and regulatory filings, with a focus on a reliable supply of quality product available to meet and sustain market demand. To this end, conventional timing for certain activities may be shifted, with some activities starting sooner, some completing later, and others potentially deferring post-filing (e.g., some aspects of process optimization). Additional activities (e.g., increased testing) may also be warranted based on the overall risk of the breakthrough product coupled with available supporting data.
MANUFACTURING CONSIDERATIONS FOR BREAKTHROUGH DRUG DEVELOPMENT
Some critical product and process characterization activities could be addressed earlier and may facilitate manufacturing readiness for breakthrough products. While the considerations below may aid in introducing efficiencies into the development process, they are not intended to be prescriptive, rather reflective of best practices based on prior experiences or discussions, and rely on establishing early and robust communications with the FDA to ensure suitability with the specific development program. Where appropriate, molecule-specific recommendations are noted for consideration.
In General
& Selection of the best molecular candidate for development based on physical-chemical properties and the pharmacokinetic (PK) profile for small molecule drugs or screening for and engineering out, where possible, hot spots for degradation or undesired modifications for biologic drugs & Ensuring the fit of candidate molecules into the manufacturer's platform for drug substance (DS) and drug product (DP) and related processes to improve speed and robustness & Incorporating preliminary quality target product profile (QTPP) and bridging in the development of clinical service dosage forms for early clinical studies (i.e., phase I), which may generate data to support a breakthrough designation (e.g., identification of whether enabling formulations are needed to support rapid development)
Biologics
& Use of cell line and vector constructs for which significant prior knowledge/platform knowledge is available (e.g., viral safety aspects), with the clone selected for phase I studies, ideally carrying through to commercialization, thus minimizing any comparability concerns arising from cell line changes; appropriate methods should be used to establish clonality & Assuring preliminary cell line stability for launch should be demonstrated (e.g., limit of in vitro cell age validation) & Design and use of host cell protein assays that are comprehensive in their coverage and can be used for multiple products (from the early stages of development and all the way through commercialization) 2) is included to provide additional examples of opportunities available that might be considered to accelerate traditional CMC a pproaches for drug development a nd manufacturing to ensure early access to patients. These proposed strategies will be supplemented with examples (Annex 1) of actual experiences that companies have had working with FDA to implement some of these approaches for expediting approval of breakthrough drug products.
Process and Formulation Development Considerations
Expedited clinical development programs for breakthrough therapy products will shorten the time available to optimize phase III and commercial manufacturing processes. This will necessitate prioritization of development efforts on process reliability over yield and cost of goods. As a result, process and formulation optimization may need to be deferred to post-approval; if it can be determined, there is no impact on patient safety or product availability. Some activities that might be considered to speed development activities include the following: 
Process Validation Considerations
Process characterization/process validation (PC/PV) studies impacting patient safety must be complete prior to filing. In addition, sufficient process characterization data from clinical and pilot scale lots should be completed to assure process capability and reliability for providing commercial product supply at launch until further PC/ PV activities are completed. The following approaches could be considered for discussion and agreement with FDA. o n t h e F D A C o m p l i a n c e P o l i c y G u i d e , C P G Section 490.100 (6), for orphan drugs to allow for product distribution concurrent with release of each conformance batch (e.g., batch specific release option). This could enable launch from a commercial site with limited number of batches but is dependent on manufacturer ensuring trust: -Prior demonstration of manufacturing consistency for clinical process material -A validation protocol for commercial material and at least one executed batch record at time of filing -Robust Quality Systems able to effectively manage Corrective and Preventive Actions (CAPAs) and change management
Analytical Development Considerations
Analytical method development strategies for frontloading of analytical understanding to balance more limited process robustness and support future comparability exercises may include & A focus on high priority assays, including but not limited to potency for biologics and content, impurities, and dissolution for small molecules to ensure suitability for control system 
Control Strategy Considerations
Control strategy, based on limited manufacturing experience, but ensuring patient safety and efficacy, may consider, & Launching with a provisional control system that ensures consistent product and upgrading the control system postapproval with more manufacturing experience and completion of process validation, such as -Filing with an expanded monitoring program with more tests initially, more assay controls, and justify elimination of some tests post-approval as more knowledge is accumulated -Filing with broader in process controls (IPC) and product specification acceptance criteria at launch and reevaluating post-approval for specifications that are linked to process consistency -Filing with preliminary critical process parameters (CPPs) and CQAs Pharmaceutical Quality System (PQS) Alignment with BT Product Development Considerations PQS requirements must be adhered to for breakthrough product development while providing appropriate flexibility to accommodate accelerated activities for breakthrough product development timelines. Thus, the accelerated development PQS strategy for each product will be unique, as it depends on the timing of the BT designation, & Flexibility, based on molecule, available product, and platform knowledge will be required & Only those activities with no impact on patient safety or product supply should be considered to be deferred & A quality risk assessment must be applied to all activities that will be deferred, and the rationale, and controls needed to ensure deferred activities are completed documented & Some activities that are normally completed prior to license application may need to be deferred and submitted: -Post-submission, complete at inspection -Post-inspection, prior to approval -Post-market commitments & The manufacturing readiness plan can be used for developing internal filing and inspection readiness checklists to ensure all deferred activities are completed or addressed -Any PQS deferrals must be documented in a manufacturing readiness plan and monitored to ensure completion
BALANCING RISK OF LESS CMC DATA AT TIME OF FILING VERSUS PATIENT BENEFIT
In spite of front-loading certain critical product and process characterization activities, it may not be possible in the limited timeframes available to complete all CMC/GMP activities at the time of filing and launch of a breakthrough product. To address this possibility, manufacturers should develop a manufacturing readiness plan, which aligns the timeline for completing the manufacturing activities with those of the clinical development program. This plan should address all manufacturing sites and their suitability and readiness for development and launch of the breakthrough product, the design and implementation of critical characterization tools, the validation approach for process and methods, stability data to support adequate expiration dating for the product, and delineation of responsibilities for the development and commercial teams in addressing these issues. Where gaps exist in completing certain activities, a risk assessment should be performed, addressing the availability of less CMC information at the time of filing and product launch versus patient benefit. This should be coupled with a risk mitigation plan to address these risks either prior to launch or through the use of a post-approval life cycle management plan.
The manufacturing readiness plan and risk assessment should form the basis for discussion and agreement with FDA prior to filing the marketing application. As part of this plan, below are several proposed examples of CMC/GMP activities that may be considered as incomplete at the time of filing and launch of a breakthrough drug product: A fundamental assumption is that risk assessments demonstrate that having less data at the time of filing and launch of a breakthrough product will not compromise patient safety or product supply. Completion of any deferred CMC activities should be documented in a comprehensive PALM that is part of the marketing application and contains detailed timelines, deliverables, and types of regulatory filing to be completed post-approval.
FLEXIBILITY IN TYPE AND EXTENT OF MANUFACTURING DATA FOR MARKETING APPROVAL OF BREAKTHROUGH DRUG
FDA approval standards for marketed drugs require demonstration of substantial evidence of effectiveness, safety, and product quality. FDA's expectation for pharmaceutical quality is the same for all drugs. However, FDA regulations for orphan drugs do allow for flexibility and scientific judgment in applying approval standards, in terms of the amount and type of data needed for a particular drug to meet the statutory standards. This rationale is stated in FDA's final guidance on Expedited Programs for Serious Diseases (2) which states that the BFDA may exercise some flexibility on the type and extent of manufacturing information that is expected at the time of submission and approval for certain components (e.g., stability updates, validation strategies, inspection planning, manufacturing scale-up).^Open and transparent discussions with FDA on balancing (and mitigating) risk of less CMC/GMP information at the time of filing versus patient benefit should take place prior to filing the marketing application.
SPONSOR/FDA INTERACTIONS DURING DEVELOPMENT AND REVIEW OF BREAKTHROUGH DRUGS
In addition to a risk-based, front-loaded development plan undertaken by the manufacturer to expedite ratelimiting steps in CMC/GMP for breakthrough drug products, the agency can work with manufacturers on risk-based solutions that facilitate expedited development and review timelines without compromising availability of an adequate supply of safe and effective products for patients. A few areas for consideration are as follows:
& The traditional and time-consuming process of formal meeting requests, scheduling, briefing documents, and written responses may not be appropriate in the environment of an accelerated breakthrough therapy drug development program. More flexible approaches to ensuring information exchange and understanding should be considered to facilitate expediting development and review. Formal meetings should be reserved for more comprehensive program discussions or critical review milestones. -Submission of the dissolution method development report and dissolution specification setting strategy for early review by FDA Biopharmaceutics reviewers -Additional real-time stability data on commercial product -Additional batch data to support validation & Discuss rolling submission of module 3 components to enable more rapid access to CMC and facility data to facilitate preapproval inspection scheduling and conduct; Gain early and frequent access to reviewers via teleconferences to resolve questions, avoid delays, and provide clarity on specific concerns & For small molecules, flexibility on the qualification of regulatory starting materials (RSMs), impurities, and impurity controls, perhaps accepting something on an interim basis with a post-marketing commitment to reevaluate these controls after launch. Impurities and their associated controls, including RSMs, should be considered in light of the clinical indication and the potentially life-saving nature of the drug. It may be necessary for drugs which have not been fully optimized at the time of launch to allow for wider initial controls which can be adjusted and refined as more experience is gained in commercial manufacturing provided product safety and quality will not be impacted
CONCLUSION
Breakthrough therapies offer significant patient benefits, but the reduced timelines introduce significant CMC/GMP challenges for product development as well as resource commitments to align the development and commercial organizations. Each breakthrough drug development program will have different risks and constraints, so the specific CMC/ GMP approaches will vary by product and timing of the breakthrough designation. Through careful planning and a thorough understanding, by all parties, of the requirements and timeframes, some activities may be optimized post-approval. Leveraging prior knowledge, platform data, and use of comparability protocols are key considerations for developing a breakthrough drug product. Additional considerations include the use of initial product supply from a clinical process or site, use of supportive stability data from representative pilot scale lots, delaying certain process validation requirements not directly related to patient safety, and consideration of broader product quality acceptance ranges for non-critical quality attributes until further manufacturing experience is gained. As a result, these programs will generate significant post-approval CMC efforts and phase IV commitments to address control system updates, process optimization where needed, and site transfers. The key to success is open and transparent communications with FDA to ensure the development program delivers an adequate supply of safe and efficacious product to patients. 
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ANNEX 1
Case studies of actual challenges encountered by sponsors during BT development and flexibilities that were agreed upon with the FDA to ensure product safety and availability at the time of approval. decoupling DS Process Performance Qualification (PPQ) from DP PPQ, enabling almost parallel execution and completion of DS and DP PPQ activities, both of which were rate-limiting to the CMC file. This was enabled by ensuring no significant process changes were implemented between the clinical GMP DS batches used for DP PPQ and the subsequent DS PPQ batches, saving 4-6 months in the development timeline without incurring additional quality or patient safety/efficacy risk & To meet the projected commercial and clinical demand, an additional drug substance manufacturing site was rapidly brought online prior to BLA filing. Through multiple interactions with the FDA, licensure was sought for two drug substance manufacturing facilities, one that was the initial clinical supply site and, a second larger CMO site (licensure of this site was based on a strong analytical comparability package, the approach and content of which were discussed with the FDA via frequent interactions) & The FDA partnership was critical to rapid resolution of multiple CMC issues, especially since this was Merck's first monoclonal antibody filing with the FDA. During the final stages of the review of the BLA application, the field office site inspections were not synchronized with early action by the review division-this resulted in removal of one of the manufacturing sites from the BLA, which was subsequently submitted for review and approved very rapidly & In addition to the rapid pace of development of this molecule, along with multiple sites, the dosage form also transitioned from a lyophilized powder for solution for infusion to a liquid vial. This supply strategy was discussed and reviewed with FDA, in advance, resulting in the recent approval of the post-approval supplement for the liquid vial, based on analytical comparability in the previously agreed upon strategy & A process/product-specific host cell protein (HCP) method for measurement of host cell impurities in the drug substance was not in place at the time of designation. Upon FDA review, a well-characterized commercially available HCP assay, demonstrating appropriate coverage and clearance in the process, was used for initial commercial release. During BLA review, a postmarketing commitment to develop a process/productspecific HCP assay was agreed to. This allowed development, bridging, and validation of this HCP method off critical path to initial approval, ensuring that the interim solution did not pose any patient safety/efficacy risk. Alternatively, inclusion of the process/product-specific HCP assay in the BLA filing would have resulted in a minimum of 6-9-month delay & The importance of frequent and data-driven interactions with the FDA was critical to the success of CMC development for this drug Example no. 3: Bristol-Myers Squibb-Opdivo® (nivolumab) was approved in December, 2014. Opdivo works by inhibiting the PD-1 protein and is intended for patients who have been previously treated with ipilimumab, for melanoma patients whose tumors express BRAF V600, and for use after treatment with ipilimumab and a BRAF inhibitor. The following flexibilities allowed for development of a complete package: & Final cell-based bioassay was not available until after PPQ batches -Used frozen samples (release and stability) to allow testing following method validation to justify acceptance criteria & DS process changes allowed for improved robustness and facilitated future transfers to additional sites -Introduced modifications to downstream or purification processing steps prior to manufacture of commercial supplies; no change in cell line or upstream process -Type B and type C meeting to align on strategy; Provided preliminary comparability data, including Comparison of release and extended characterization analytical data Side-by-side degradation profile at stress conditions Full scale in-process control data comparison -Able to bridge stability data to allow expiry to be based on studies performed using material from the clinical process & To meet the compressed timelines for NDA submission and approval, PPQ activities of DP and PPQ of DS were conducted in parallel. This was made possible because no major process changes were implemented between DS manufacturing process used to manufacture the pivotal clinical batches and eventual commercial process & The commercial DS manufacturing site was different from the site where earlier clinical batches were manufactured. Comparability data of clinical batches to commercial batches was used to support the change. Both clinical process and commercial process used similar control strategy and no major changes to the manufacturing process were made between the two sites & An alternate more discriminating dissolution method was developed and validated prior to NDA submission. However, available data generated using the new method was limited and not sufficient to propose a specification using this method. A commitment was made to collect additional data using the new method and revise the dissolution specification post-approval & Responses to FDA queries and request for information during review were completed promptly with turnaround time of 24-48 h & Labels, cartons, and other launch materials were printed at risk in order to minimize delay in commercial launch after approval Established and documented; possibly broader specifications as little data are available May include more elements than traditional specification due to limited data set and/or some parameters where the data will be reported but acceptance criteria not defined Commitment to update (rationalize) after x time or y batches, based on pre-defined criteria and to reassess the control strategy. Impurity assessment Impurities identified, risk assessed and controlled Controlled mainly by process knowledge rather than specification testing Impurities identified, risk assessed and controlled Higher level of control by specification testing (could include intermediates) may be needed until sufficient data available to support greater reliance on process control
Shelf-life Shelf-life at launch based upon defined length of stability data on defined batch types/sizes (ICH Q1A) Post-approval extension as further data emerges Launch product will be supported by (ongoing) stability studies, but ICH-conform data may be limited. Negotiate employment of lean stability strategies (including stress conditions), use of stability models, and extrapolation for supporting shelf-life with competent authorities, enhanced use of scientifically relevant supporting data from earlier batches, and possibly more than one batch annually in ongoing stability Support of adequate shelf-life with use of highly protective packaging/restrictive storage conditions as appropriate to the elicited degradation mechanisms Post-approval strategies will depend on formulation strategy and may also involve novel approaches 
